title: [Antiphospholipid syndrome and pregnancy].
abstract: Antiphospholipid syndrome (APS) is the association of antiphospholipid antibodies with thromboses and/or obstetric morbidity. Obstetric morbidity includes recurrent first trimester loss, stillbirth, intrauterine death, preeclam-psia, premature birth and fetal growth restriction. Although current treatment regimens including aspirin and low-molecular weight heparin have improved pregnancy outcomes, 30% of affected women have pregnancy complica-tions. Women with APS are therefore high-risk pregnancies who should be monitored in specialist centres according to international standards.
authors.forename: Karen
authors.initials: K
authors.lastname: Schreiber
authors.forename: Jacob Alexander
authors.initials: JA
authors.lastname: Lykke
authors.forename: Jens
authors.initials: J
authors.lastname: Langhoff-Roos
authors.forename: Henriette Svarre
authors.initials: HS
authors.lastname: Nielsen
authors.affiliation: sj@dadlnet.dk.
authors.forename: Søren
authors.initials: S
authors.lastname: Jacobsen
mesh_terms: D000925:Anticoagulants / Q000627:therapeutic use; D000962:Antimalarials / Q000627:therapeutic use; D016736:Antiphospholipid Syndrome / Q000145:classification / Q000150:complications* / Q000188:drug therapy; D001241:Aspirin / Q000627:therapeutic use; D005260:Female; D006495:Heparin, Low-Molecular-Weight / Q000627:therapeutic use; D006801:Humans; D011247:Pregnancy; D011248:Pregnancy Complications / Q000209:etiology*; D018566:Pregnancy, High-Risk
chemical_list: D000925:Anticoagulants; D000962:Antimalarials; D006495:Heparin, Low-Molecular-Weight; D001241:Aspirin